Eli Lilly Invests $100M in AI Biotech Absci

Eli Lilly just dumped $100 million into Absci, a Vancouver biotech startup that went public just a couple of years ago — and this isn’t just any investment. It’s an underwritten offering, meaning big banks are buying shares upfront to signal massive confidence in Absci’s future. With its AI-powered drug discovery platform, Absci is poised to revolutionize how medicines are developed — potentially accelerating treatments for countless diseases. This partnership between a pharma giant and a tech-forward biotech could reshape the entire industry, fueling Absci’s R&D and putting them firmly on the map as a leader in next-gen medicine. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/a4476c3a107846d2